Cardiff Oncology, Inc. Share Price

Cardiff Oncology, Inc. Share Price

NASDAQ: CRDF | Micro Cap
$0.88
-$0.04 (-4.53%) Last updated on 31 Oct, 2026 | 01:12 IST
  • Performance
  • Chart
  • Fundamentals
  • Quarterly P&L
  • Annual P&L
  • About
  • Price history
  • FAQs

Cardiff Oncology, Inc. Stock Performance

Open
$0.92
Prev. Close
$0.92
Circuit Range
N/A
Day Range
$0.87 - $0.92
Year Range
$0.76 - $3.31
Volume
2,758
Average Traded
$0.90

Cardiff Oncology, Inc. Share Price Today

As of 31 October 2026, Cardiff Oncology, Inc.'s share price is $0.88. The stock opened at $0.92, compared to its previous close of $0.92. During today's trading session, Cardiff Oncology, Inc.'s share price traded between $0.87 and $0.92, with an average price of $0.90. Over the past 52 weeks, the stock has recorded a high of $3.31 and a low of $0.76. In terms of performance, Cardiff Oncology, Inc.'s share price has declined by 49.22% over the last six months and is down 62.81% on a year-on-year basis.

Cardiff Oncology, Inc. Share Price Chart

Line chart of the Cardiff Oncology, Inc. price trend over the selected period. The price fell overall, ranging from 0.87 to 0.89, ending at 0.88.
$0.87$0.92
L
Show Current Price
H

Cardiff Oncology, Inc. Stock Fundamentals & Key Indicators

Market Cap
$58.55M
PE Ratio (TTM)
N/A
Dividend Yield
0.00%
EPS (TTM)
$-0.52
Revenue (TTM)
$590.00M
Return On Equity (TTM)
-151.05%
Profit Margin
-7776.27%
Debt to Equity
0.00
Quarterly Earnings Growth YoY
17.94%

Cardiff Oncology, Inc. Quarterly Profit & Loss

All figures in USD

ParticularsSep 2025Dec 2025Mar 2026Jun 2026
Revenue$0.12$0.24$0.04$0.10
Net Profit-$11.26-$7.22-$12.35-$9.24
Net Profit Margin-9383.33%-3008.33%-30875.00%-9240.00%
Income ChangeN/A35.88%-71.05%25.18%

Cardiff Oncology, Inc. Annual Profit & Loss

All figures in USD

Particulars2022202320242025
Revenue$0.39$0.49$0.68$0.59
Net Profit-$38.73-$41.47-$45.46-$45.88
Net Profit Margin-9930.77%-8463.27%-6685.29%-7776.27%
Income ChangeN/A-7.07%-9.62%-0.92%

About Cardiff Oncology, Inc.

Cardiff Oncology Inc is a clinical-stage biotechnology company advancing cancer treatments focused on PLK1 inhibition, a validated oncology target with practice-changing potential. Its main asset, onvansertib, is a specific, oral PLK1 inhibitor currently being evaluated in a Phase 2 trial for first-line treatment of RAS-mutated metastatic colorectal cancer (mCRC), addressing a large, underserved patient population with high unmet need. Onvansertib is also under investigation in other PLK1-driven cancers through ongoing investigator-initiated trials and has shown robust single agent clinical activity in hard-to-treat tumors. By targeting tumor vulnerabilities, to overcome treatment resistance and deliver improved clinical outcomes for patients.

Cardiff Oncology, Inc. Historical Returns

Share price history by day, with open and close prices and the day's change
MonthOpenCloseChange %
Oct 2026
$1.20
$0.87
-27.50%
Sep 2026
$1.02
$1.20
+21.46%
Aug 2026
$0.87
$0.99
+14.88%
Jul 2026
$1.29
$0.86
-33.59%
Jun 2026
$1.68
$1.29
-32.20%
May 2026
$1.74
$1.91
+10.72%
Apr 2026
$1.69
$1.73
+6.15%
Mar 2026
$1.87
$1.63
-15.80%
Feb 2026
$1.70
$1.93
+10.92%
Jan 2026
$2.79
$1.74
-37.97%
Dec 2025
$2.25
$2.81
+23.03%
Nov 2025
$2.34
$2.28
-3.18%

CRDF Share Price FAQs